Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.